StreetInsider.com News Articles

Form ARS TuHURA Biosciences, Inc. For: Dec 31

Thu, 09 Jul 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260709/26753281.html

Form ARS TuHURA Biosciences, Inc. For: Dec 31

Thu, 09 Jul 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260709/26753281.html

Form DEFA14A TuHURA Biosciences, Inc.

Thu, 09 Jul 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260709/26753267.html

Form DEFA14A TuHURA Biosciences, Inc.

Thu, 09 Jul 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260709/26753267.html

Form DEF 14A TuHURA Biosciences, Inc. For: Aug 18

Thu, 09 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260709/26753247.html

Form DEF 14A TuHURA Biosciences, Inc. For: Aug 18

Thu, 09 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260709/26753247.html

Form 8-K TuHURA Biosciences, Inc. For: Jun 30

Tue, 07 Jul 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260707/26742834.html

Form 8-K TuHURA Biosciences, Inc. For: Jun 30

Tue, 07 Jul 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260707/26742834.html

Form PRE 14A TuHURA Biosciences, Inc. For: Aug 18

Fri, 26 Jun 2026 17:27:00 -0400

si-local-file:///var/storage/secattach/20260626/26700036.html

Form PRE 14A TuHURA Biosciences, Inc. For: Aug 18

Fri, 26 Jun 2026 17:27:00 -0400

si-local-file:///var/storage/secattach/20260626/26700036.html

Form 8-K TuHURA Biosciences, Inc. For: Jun 17

Wed, 17 Jun 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260617/26660390.html

Form 8-K TuHURA Biosciences, Inc. For: Jun 17

Wed, 17 Jun 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260617/26660390.html

TuHURA Biosciences (HURA) Reiterated at Market Outperform by Citizens

Tue, 16 Jun 2026 05:17:41 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $9.00 price target on TuHURA Biosciences (NASDAQ: HURA).

The analyst commented, "We are encouraged to see TuHURA Biosciences kick off clinical development in the acute myeloid leukemia (AML) space, where menin inhibitors have demonstrated that significant value can be created. HURA announced the IND filing for anti-VISTA mAb, TBS-2025, after the FDA aligned with prior guidance on the development pathway for monotherapy and combination with menin inhibitors for AML. Following written responses related to the company's proposed Phase 1b/2 development plan, HURA is targeting study initiation in 2H26. We maintain our

TuHURA Biosciences files IND for TBS-2025 antibody in blood cancers

Mon, 15 Jun 2026 07:49:38 -0400

TuHURA Biosciences Inc. (NASDAQ: HURA) filed an Investigational New Drug application with the U.S. Food and Drug Administration for its TBS-2025 VISTA inhibiting antibody to treat molecularly defined subsets of acute myeloid leukemia and other blood-related cancers.

The IND filing follows guidance from the FDA on the development pathway for both monotherapy and combination treatments with menin inhibitors for AML. The FDA indicated that a requested meeting would not be necessary and will provide written responses to questions about the company's proposed Phase 1b/2 development plan for TBS-2025 in AML.

TuHURA targets initiation of the Phase 1b/2 study in the second half

TuHURA Biosciences files IND for TBS-2025 antibody in blood cancers

Mon, 15 Jun 2026 07:49:38 -0400

TuHURA targets initiation of the Phase 1b/2 study in the second half

TuHURA Biosciences files IND for TBS-2025 antibody in blood cancers

Mon, 15 Jun 2026 07:49:38 -0400

TuHURA targets initiation of the Phase 1b/2 study in the second half

TuHURA Biosciences files IND for TBS-2025 antibody in blood cancers

Mon, 15 Jun 2026 07:49:38 -0400

TuHURA targets initiation of the Phase 1b/2 study in the second half

TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers